<2>Puberty Blockers Trial: Professor Jacob George Excused from Involvement as Data Linkage Study is Greenlit
<3>Controversy Surrounds 주요 UK Clinical Trial
The Pathways clinical trial, a UK-based study aimed at assessing the effects of puberty blockers on young people with gender incongruence, has been mired in controversy. Just a week after the trial was paused by the Medicines and Healthcare Products Regulatory Agency (MHRA) on 20 February,1 the regulator announced that it was excusing its chief medical and scientific officer, Jacob George, from any further involvement with the Pathways clinical trial.
<3>Background on the Controversy
The MHRA specially created the role for George—who only started in January this year—to oversee its scientific, research, and innovation activities. However, the move followed the surfacing of now deleted social media posts he had made before his appointment. Although the MHRA has not published the relevant posts, screengrabs of posts published between April 2023 and August 2024 have since circulated on social media.
<3>Deleted Social Media Posts Circling on Social Media
In one George branded the International Olympic Committee a “disgrace” for its decision to allow